CoChat

Dyslipidemia in Obesity: Mechanisms and Potential Targets

Open access

The DOI matches its Crossref record; 166 of the 169 references it cites were found in a registry or an index; 5 of the 56 sources its claims cite were checked for support.

Abstract

Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia.

Overview

CoChat Summary

TL;DR

This narrative review describes how obesity-related insulin resistance, impaired triglyceride lipolysis, increased free fatty acid flux, and altered apolipoprotein/complement metabolism produce the characteristic dyslipidemia of high triglycerides, small dense LDL, and low HDL-C. It summarizes lifestyle and pharmacological approaches, emphasizing weight loss, statins, fibrates, niacin, omega-3 fatty acids, and apoB/non-HDL-C as treatment targets.

Key findings

  • The hallmark of obesity dyslipidemia is elevated fasting and postprandial TG, small dense LDL, low HDL-C, and normal or slightly increased LDL-C, with increased apoB; hypertriglyceridemia may be the major cause of the other lipid abnormalities.
  • Mechanisms include insulin resistance with enhanced hepatic FFA flux, hepatic overproduction of apoB-containing lipoproteins, reduced LPL mRNA in adipose tissue and LPL activity in skeletal muscle, elevated apo C-III, increased CETP-mediated lipid exchange, hepatic lipase action, and reduced LDL receptor expression; ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects versus lean controls.
  • Atherogenic features include small dense LDL with a five-day residence time and chylomicron remnants that contain approximately 40 times more cholesterol per particle than LDL; postprandial hyperlipidemia with atherogenic remnants is especially linked to visceral obesity.
  • Treatment findings include: weight loss of 4–10 kg reduced LDL-C by 12% and increased LDL receptor mRNA by 27%; moderate weight loss of approximately 10% reduced postprandial TG by 27%–46%; fibrates reduce TG by approximately 30%, LDL-C by 8%, and increase HDL-C by an average of 9%; niacin lowers TG by 15%–35% and raises HDL-C by 10%–25%; omega-3 fatty acids reduce plasma TG by 25%–30%; ezetimibe gives an additional 20% LDL-C lowering.

Methods

  • Narrative review of lipid metabolism in obesity, including general lipoprotein metabolism, obesity-induced changes, FFA/inflammation interplay, lifestyle interventions, and pharmacological treatment.
  • No primary data or study sample; the paper synthesizes published literature and cites prior studies, including metabolic ward studies, stable isotope studies, randomized trials, and meta-analyses.
  • Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal quality assessment is described.

Limitations

  • The paper does not explicitly state limitations of the review itself. It notes evidence gaps, including that specific data on niacin plus statins in obesity remain scarce, that increasing HDL-C by exercise remains controversial, and that controversy exists about fibrate therapy on top of statin therapy.
  • Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal risk-of-bias assessment, and it reports no primary outcomes of its own.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu5041218

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The hallmark of dyslipidemia in obesity is hypertriglyceridemia in part due to increased free fatty acid (FFA) fluxes to the liver, which leads to hepatic accumulation of triglycerides (TG). This leads to an increased hepatic synthesis of large very low density lipoproteins (VLDL) 1, which hampers the lipolysis of chylomicrons due to competition mainly at the level of lipoprotein lipase (LPL) with increased remnant TG being transported to the liver. Lipolysis is further impaired in obesity by reduced mRNA expression levels of LPL in adipose tissue and reduced LPL activity in skeletal muscle. Hypertriglyceridemia further induces an increased exchange of cholesterolesters (CE) and TG between VLDL and HDL and low density lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to decreased HDL-C concentrations and a reduction in TG content in LDL. In addition, hepatic lipase (HL) removes TG and phospholipids from LDL for the final formation of TG-depleted small dense LDL. The intense yellow color represents cholesterol, whereas the light yellow color represents the TG content within the different lipoproteins. Obesity induced increases in metabolic processes are marked with green arrows, whereas reductions are marked with red arrows.
Figure 1 The hallmark of dyslipidemia in obesity is hypertriglyceridemia in part due to increased free fatty acid (FFA) fluxes to the liver, which leads to hepatic accumulation of triglycerides (TG). This leads to an increased hepatic synthesis of large very low density lipoproteins (VLDL) 1, which hampers the lipolysis of chylomicrons due to competition mainly at the level of lipoprotein lipase (LPL) with increased remnant TG being transported to the liver. Lipolysis is further impaired in obesity by reduced mRNA expression levels of LPL in adipose tissue and reduced LPL activity in skeletal muscle. Hypertriglyceridemia further induces an increased exchange of cholesterolesters (CE) and TG between VLDL and HDL and low density lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to decreased HDL-C concentrations and a reduction in TG content in LDL. In addition, hepatic lipase (HL) removes TG and phospholipids from LDL for the final formation of TG-depleted small dense LDL. The intense yellow color represents cholesterol, whereas the light yellow color represents the TG content within the different lipoproteins. Obesity induced increases in metabolic processes are marked with green arrows, whereas reductions are marked with red arrows.CC BY · PubMed Central
Figure 2 Free fatty acid (FFA) uptake and its related triglyceride (TG) synthesis in adipocytes are highly depended of C3adesArg or acylation-stimulation protein (ASP). Chylomicrons and VLDL undergo lipolysis by lipoprotein lipase (LPL) with subsequent release of FFA into the circulation. The FFA are then transported into the subendothelial space by the scavenger receptor CD36 and other transporters where C3adesArg plays an important role in the subsequent TG synthesis for storage of lipids in the adipocytes. C3adesArg is the most potent molecule known, which induces transmembrane transport of FFA and its intracellular esterification into TG within adipocytes. C3adesArg is metabolized from complement component (C) 3a by carboxypeptidase N and C3a is again the splice product from C3, which is formed in case of complement activation. Postprandial lipemia is directly linked to complement activation. For example, adipocytes secrete C3 when incubated with TG-rich lipoproteins like chylomicrons or very low density lipoproteins (VLDL), but also Factor B and Factor D, thereby causing activation of the complement cascade.
Figure 2 Free fatty acid (FFA) uptake and its related triglyceride (TG) synthesis in adipocytes are highly depended of C3adesArg or acylation-stimulation protein (ASP). Chylomicrons and VLDL undergo lipolysis by lipoprotein lipase (LPL) with subsequent release of FFA into the circulation. The FFA are then transported into the subendothelial space by the scavenger receptor CD36 and other transporters where C3adesArg plays an important role in the subsequent TG synthesis for storage of lipids in the adipocytes. C3adesArg is the most potent molecule known, which induces transmembrane transport of FFA and its intracellular esterification into TG within adipocytes. C3adesArg is metabolized from complement component (C) 3a by carboxypeptidase N and C3a is again the splice product from C3, which is formed in case of complement activation. Postprandial lipemia is directly linked to complement activation. For example, adipocytes secrete C3 when incubated with TG-rich lipoproteins like chylomicrons or very low density lipoproteins (VLDL), but also Factor B and Factor D, thereby causing activation of the complement cascade.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 28 Not checked · 6 Own results and interpretations

14 more claims

Create a free account to see all 38 claims and to verify the 51 references still open.

See all claims — free account
  • It may state two separate claims as one. 18
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 166 references

Cited by

See all 1,665

Metadata

Authors
Klop, B., Elte, J., & Cabezas, M.
Affiliations
Sint Franciscus Gasthuis (NL)
Corresponding author
Cabezas, Manuel
Venue
Nutrients
Publisher
MDPI AG
Published
2013-04-12
Volume
5
Issue
4
Pages
1218-1240
ISSN
2072-6643 (ISSN-L)
OpenAlex
W1985399572
Cited by
1,665
References
169
Citations by year
2026: 90 · 2025: 157 · 2024: 194 · 2023: 210 · 2022: 196 · 2021: 195 · 2020: 138 · 2019: 117 · 2018: 76 · 2017: 74 · 2016: 75 · 2015: 63 · 2014: 65 · 2013: 12
FWCI
10.53
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
obesity, dyslipidemia, metabolic syndrome, insulin resistance, small dense LDL, postprandial hypertriglyceridemia, apolipoprotein B, hepatic lipogenesis, adipose tissue inflammation, endothelial dysfunction, cardiovascular risk, lipid metabolism, obesity treatment
MeSH terms
Hypolipidemic Agents, Humans, Insulin Resistance, Lipids, Obesity, Risk Factors, Biomarkers, Comorbidity, Treatment Outcome, Inflammation Mediators, Caloric Restriction, Risk Reduction Behavior, Dyslipidemias, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dyslipidemia in Obesity: Mechanisms and Potential Targets. https://app.cochat.ai/papers/10.3390/nu5041218
The paper
Klop, B., Elte, J., & Cabezas, M. (2013). Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. https://doi.org/10.3390/nu5041218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.